February 18, 2020 9:03pm

A scorecard of earnings of 35 covered  companies

The current LPS (loss per share) or net income, cash positions i.e. "runways" - is a reflection of this universe's investing "status"

 


COMPANY Q4/19

SYMBOL NET INCOME Q4/19 LOSS Q4/19 LPS Q4/19 CASH RUNWAY
Aduro Biotech, Inc. ADRO          
Alnylam Pharmaceuticals ALNY  

-$221.2 M

-$886.1 M, FY19

-$1.98

-$6.50, FY19

$1.55 B

 Not

needed

Applied Genetic Technologies AGTC          
Athersys, Inc. ATHX          
Adverum Biotechnologies, Inc. ADVM          
Audentes Therapeutics BOLD          
AxoGen, Inc. AXGN          
Bellicum Pharmaceuticals BLCM          
BioLife Solutions, Inc. BLFS          
Biostage, Inc. BSTG          
bluebird bio BLUE  

-$323.3 M

-$789.6 M,FY19

  $124 B 2022
Brainstorm Cell Therapeutics BCLI  

No Q4

-$23.2 M, FY19

No Q4

-$1.06, FY19

$600 K 2020
Caladrius Biosciences. CLBS          
Cellectis SA CLLS          
CRISPR Therapeutics CRSP

+$30.5 M

+$6.9 M, FY19

+$0.51

+$1.17

  $943.8 M 2020
Editas Medicine EDIT          
Fate Therapeutics FATE          
Global Blood Therapeutics GBT          
Homology Medicine FIXX          
Intellia Therapeutics NTLA          
Precigen (fomerly Intrexon (XON) XON          
Ionis Pharmaceuticals IONS          
Mesoblast Limited MESO          
MiMedx Group, Inc MDXG          
Pluristem Therapeutics, Inc. PSTI          
ReNeuron Group PLC RENE.L          
Regenxbio RGNX          
Sage Therapeutics SAGE          
Sangamo Biosciences, Inc. SGMO          
Solid Biosciences SLDB          
Stemline Therapeutics, Inc. STML          
Ultragenyx RARE  

-$93.8 M

-$402.7 M, FY19

-$1.62

-$7.12, FY19

$760.4 M 2021
uniQure N.V. QURE          
Verastem, Inc. VSTM          
Vericel Corporation VCEL          
Voyager Therapeutics VYGR